Association between aspirin dose and outcomes in patients with acute Kawasaki disease

- 3 Takanori Suzuki, MD,¹ Nobuaki Michihata, MD, MPH, PhD,² Yohei Hashimoto, MD,
- 4 PhD,³ Tetsushi Yoshikawa, MD, PhD,¹ Kazuyoshi Saito, MD, PhD,¹ Hiroki Matsui,
- 5 MPH,³ Kiyohide Fushimi, MD, PhD,⁴ Hideo Yasunaga, MD, PhD³
- 6 Affiliations: 1 Department of Pediatrics, Fujita Health University, Aichi, Japan
- 7 2 Department of Health Services Research, Graduate School of Medicine, The University
- 8 of Tokyo, Tokyo, Japan
- 9 3 Department of Clinical Epidemiology and Health Economics, School of Public Health,
- 10 The University of Tokyo, Tokyo, Japan
- 11 4 Department of Health Policy and Informatics, Tokyo Medical and Dental University
- 12 Graduate School of Medicine, Tokyo, Japan
- 13 Correspondence to: Nobuaki Michihata, MD, MPH, PhD, Department of Health
- 14 Services Research, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo,
- 15 Bunkyo-ku, Tokyo 113-0033, Japan
- 16 E-mail: michihata@m.u-tokyo.ac.jp
- 17 Tel: +81-3-5841-1887
- 18 Fax: +81-3-5841-1888
- 19 Short title: Association between aspirin dose and KD outcomes
- 20 Conflict of Interest Disclosures: All authors have no potential conflicts of interest to
- 21 disclose.
- 22
- 23 Funding/Support: This work was supported by grants from the Ministry of Health,
- 24 Labour and Welfare, Japan (21AA2007 and 20AA2005), and the Ministry of
- 25 Education, Culture, Sports, Science and Technology, Japan (20H03907).
- 26 All authors have no financial relationships relevant to this article to disclose.
- 27
- 28 **Open Access:** We do not want open access.
- 29

- 30 Data sharing statement: The datasets analyzed during the current study are not publicly
- 31 available due to contracts with the hospitals providing data to the database.
- 32 Abbreviations: ADL: activities of daily living; CAA: coronary artery abnormalities; CI:
- 33 confidence interval; ICD-10: International Classification of Diseases, Tenth Revision;
- 34 IQR: interquartile range; IVIG: intravenous immunoglobulin, KD: Kawasaki Disease;
- 35 SD: standard deviation; USD: United States Dollar
- 36 37
- 38 Keywords: Kawasaki disease, aspirin, coronary artery abnormalities, restricted cubic39 spline.
- 40 Article Summary: The study showed by restricted cubic spline that the dose of aspirin
- 41 was no significant association between aspirin escalation and CAAs in patients with42 acute KD.
- 43 What's Known on This Subject: Aspirin is standard treatments used with IVIG of
- 44 acute Kawasaki Disease (KD), Few studies have shown the most effective dosage of
- 45 aspirin to to prevent CAAs.
- 46 What This Study Adds: The dose of aspirin was no significant association between47 aspirin escalation and CAAs in patients with acute KD.
- 48 Total word count of the manuscript: 2284 words

49

50 Author contributions:

- 51 Takanori Suzuki wrote the first draft of the manuscript. Nobuaki Michihata
- 52 conceptualized and designed the study, drafted the initial manuscript, and reviewed and
- 53 revised the manuscript. Kazuyoshi Saito, Tetsushi Yoshikawa, Hiroki Matsui, Kiyohide
- 54 Fushimi, and Hideo Yasunaga conceptualized and designed the study, and coordinated
- and critically reviewed the manuscript for important intellectual content. All authors
- approved the final manuscript as submitted and agree to be accountable for all aspects of
- 57 the work.

58

61 Abstract

- 62 Background: The most effective dosage of aspirin to prevent coronary artery
- 63 abnormalities in patients with acute Kawasaki disease remains unknown. Using a
- 64 Japanese national inpatient database, this study aimed to identify the appropriate dose of
- aspirin to be prescribed to patients with acute Kawasaki disease.
- 66 Method: We used the Diagnostic Procedure Combination database to identify patients
- 67 with Kawasaki disease treated with intravenous immunoglobulin between 2010 and
- 68 2021. The outcomes included the occurrence of coronary artery abnormalities and
- 69 intravenous immunoglobulin resistance, length of stay, and medical costs. Restricted
- 70 cubic spline functions were performed to examine the association between aspirin dose
- 71 and the outcomes.
- 72 **Results**: Data of 82109 patients were extracted from the database. Non-linear
- associations were observed between aspirin dose and the outcomes. In comparison with
- an aspirin dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for coronary
- artery abnormalities was 1.40 (1.13–1.75) at 5 mg/kg/day. An aspirin dose of \geq 30
- 76 mg/kg/day did not significantly change the odds ratio for coronary artery abnormalities.
- 77 Compared with a dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for
- 78 intravenous immunoglobulin resistance was 0.87 (0.76–1.00) at 5 mg/kg/day and 0.59
- 79 (0.36–0.98) at 80 mg/kg/day. An increase in aspirin dose was associated with a shorter
- 80 length of stay and lower medical costs.
- 81 Conclusions: Low-dose aspirin may increase the risk of coronary artery abnormalities in
- 82 patients with acute Kawasaki disease; however, increasing aspirin doses beyond the
- 83 standard doses may not be associated with a reduction in coronary artery abnormalities.
- 84 High-dose aspirin showed the potential to reduce hospital stay and medical costs without
- 85 increasing complications.
- 86

88 Introduction

89	Kawasaki disease (KD) represents an acute form of systemic vasculitis, which most
90	commonly leads to acquired heart disease in children in most industrialized countries. ¹
91	The standard treatment for patients with acute KD is the administration of aspirin and
92	intravenous immunoglobulin (IVIG). As for the aspirin dose for patients with acute KD,
93	the American Heart Association guidelines for KD recommend 80–100 mg/kg/day, while
94	the Japanese Society of Pediatric Cardiology and Cardiac Surgery guidelines for KD
95	recommend 30–50 mg/kg/day in the acute KD. ^{2,3} However, various trials have
96	investigated the effectiveness of different aspirin doses for patients with acute KD.
97	Recent small-scale studies have reported no difference in coronary artery abnormalities
98	(CAAs) outcomes with aspirin doses as low as 3-5 mg/kg/day or as high as 100
99	mg/kg/day. ⁴⁻⁹ Another study found that high doses of aspirin enhanced the production of
100	tumor necrosis factor-alpha (TNF- α), which is related to the development of CAAs. ¹¹
101	Thus, the results of previous studies are controversial, and the most appropriate dose of
102	aspirin remains unknown. Conversely, it was recently reported that high-dose aspirin may
103	have a negative effect on the initial IVIG therapy during the acute febrile phase of KD. ¹⁰
104	This study aimed to examine the association between aspirin dose and outcomes in
105	patients with acute KD, using a Japanese national inpatient database.

106 Methods

107 Data source

108	For this retrospective cohort study, we used data from the Diagnosis Procedure
109	Combination database. Over 80 academic hospitals are obliged to participate in the
110	database; however, the participation of community hospitals in the database is voluntary.
111	Data for about 8 million hospitalized patients of all ages are included every year. It is
112	almost equivalent to 50% of the total acute-care hospitalizations in Japan. The database
113	includes the following information: unique identifiers of hospitals, patient baseline
114	characteristics, and diagnosis at admission, comorbidities at admission, and
115	complications after admission recorded with text data in Japanese and International
116	Classification of Diseases, Tenth Revision (ICD-10) codes; medical procedures and
117	treatments, including drug administrations, devices use, and surgical and nonsurgical
118	procedures, length of stay, discharge status, and medical cost during hospitalization.
119	Attending physicians must record diagnoses and comorbidities with reference to medical
120	records. The current study was approved by the Institutional Review Board of The
121	University of Tokyo (approval number: 3501-(5) (May 19th, 2021). The requirement for
122	informed consent was waived due to the anonymous nature of the data.

123

124 Participants

125	We identified patients diagnosed with KD (ICD-10 code: M303) between July 2010 and
126	March 2021. We included patients who were treated with initial IVIG treatment. We
127	further checked the Japanese text describing the detailed diagnoses in each case to include
128	patients with atypical KD and exclude patients with a 'suspected' diagnosis of KD. We
129	excluded patients who weighed <3 kg, >60 kg or had missing data. Patients who used
130	flurbiprofen were excluded from our study. The initial aspirin dose was defined as the
131	dose used at the same time as the initial IVIG in the acute phase of KD. We also excluded
132	initial aspirin dose <3 mg/kg/day or initial aspirin dose >90 mg/kg/day. We classified the
133	study population according to the aspirin dose at the initial treatment of IVIG: low-dose
134	group, aspirin <30 mg/kg/day; standard-dose group, 30–50 mg/kg/day; and high-dose
135	group, >50 mg/kg/day.

136 Outcomes

137 The primary outcome was the occurrence of CAAs upon discharge. CAAs were identified
138 with a recorded diagnosis of CAAs (ICD-10 code: I25.4) and/or text data of CAAs in the
139 Japanese language. The secondary outcomes were IVIG resistance, length of stay,

140	medical costs, and adverse events. We converted 1 United States dollar (USD) to 100
141	Japanese yen. IVIG resistance was defined as the use of IVIG at a total dose of \geq 4.0 g/kg
142	and/or a combination of any steroid, infliximab, cyclosporine, and/or plasma exchange
143	that was not administered during the initial IVIG treatment. The medical costs included
144	costs of surgery, drugs, laboratory tests, and other inpatient services, including food
145	expenses. We also examined adverse events after admission occurring with aspirin,
146	including Reye syndrome (ICD-10 code: G937), bleeding from the upper gastrointestinal
147	tract (ICD-10 code: K922), anemia (ICD-10 code: D5, D60-4), gastric ulcer (ICD-10
148	code: K25-6), and liver function abnormality (ICD-10 code: K719, K769) /or text data of
149	adverse events in the Japanese language.
150	Covariates

151 The baseline characteristics included sex, age, weight, height, hospital days of illness at

152 initial IVIG, use of 10% IVIG, initial steroid use, initial cyclosporine use, type of hospital,

- complex chronic conditions,¹² Japan Coma Scale at admission, transportation by 153
- ambulance, transportation from other hospitals, and hospital volume. Initial steroid use 154
- and initial cyclosporine use were defined as those concurrent with initial IVIG use. For 155
- 156 the hospital type, academic hospitals were defined as university hospitals and related

157	hospitals. The Japan Coma Scale score at admission was categorized into two groups:
158	alert and not alert. Japan Coma Scale assessment was previously clarified to be well
159	associated with the Glasgow Coma Scale assessment. ¹³ Hospital volume was defined as
160	the number of all patients with KD at each hospital every year. Hospital volume was
161	divided into tertiles so that the number of patients in each group was almost equal.
162	Statistical analysis
163	Categorical variables were presented as numbers and percentages and were compared
164	using the Fisher exact test. Continuous variables were presented as means and standard
165	deviations (SD) or medians and interquartile ranges (IQR). Non-normally distributed
166	variables (length of stay and medical costs) were compared among the three groups using
167	the Kruskal–Wallis test. The sensitivity analysis of CAAs was limited to those who had a
168	diagnosis of CAAs and were using anticoagulants, such as warfarin or clopidogrel, or
169	were undergoing cardiac catheterization.
170	Restricted cubic spline functions
171	Studies regarding the relationship between aspirin dose and outcomes converted
172	continuous measures of aspirin into categorical variables. However, this may have
173	resulted in a loss of information and a decrease in statistical power. ¹⁴ Therefore, we used

174	multivariable regression models with restricted cubic spline functions to assess the
175	potential non-linear association of aspirin dose with CAAs, IVIG resistance, length of
176	stay, and medical cost. Multivariable logistic regression models were applied for the
177	occurrence of CAAs and IVIG resistance, and multiple regression models were applied
178	for length of stay and medical cost with adjustment for age, sex, body weight, body height,
179	hospital days of illness at the initial IVIG treatment, use of 10% IVIG, initial steroid use,
180	initial cyclosporine use, type of hospital, complex chronic conditions, transportation by
181	ambulance, Japan Coma Scale at admission, transportation from another hospital, fiscal
182	year, and hospital volume. We created restricted cubic splines with five knots at
183	pre-specified locations according to the percentiles of the distribution of aspirin doses (10,
184	30, 40, 50, and 70 mg/kg/day). Tests for overall and non-linear associations were
185	performed using the χ^2 test. ¹⁵ A two-sided value of <i>P</i> <.05 was considered significant.
186	Statistical analyses were performed using the Stata software 17 (StataCorp LP, TX,
187	USA).
188	

189

191 Results

192	Patient character	ristics are shown	in Table	 Initially 	, 82,109	patients with	acute KD were
-----	-------------------	-------------------	----------	-------------------------------	----------	---------------	---------------

- 193 identified using the inclusion criteria (Figure 1). The mean age was 2.1 years (SD, 2.0),
- and the mean body weight was 12.3 kg (SD, 4.7). Of them, 47,277 (57.6%) were male.
- 195 The median total amount of aspirin was 30.1 mg/kg/day (IQR, 29.4–32.3). Regarding the
- 196 aspirin dose, the low-dose group (n=30,439) had a median of 28.9 mg/kg/day (IQR, 27.5–
- 197 29.5), the standard-dose group (n=49,646) had a median of 31.1 mg/kg/day (IQR, 30.2–

198 36.4), and the high-dose group (n=2,024) had a median of 52.1 mg/kg/day (IQR, 50.8–

- 199 58.5) (P<.001). Moreover, the high-dose group was associated with younger age, smaller
- 200 weight, lower height, longer hospital days of illness, 10% IVIG and initial steroid, initial
- 201 cyclosporine, academic hospital, the score of complex chronic conditions, and transport
- ambulance. CAAs and IVIG resistance occurred in 1817 (2.2%) and 15717 (19.1%)
- 203 patients, respectively. The median (IQR) of length of stay and medical costs was 10 days
- 204 (8.0–12.0) and 6454 USD (5299–8169), respectively.

- proportions of CAAs (2.0%, P < .001), shorter length of stay (median, 10 days; P < .001),
- and lower medical costs (median, 6440 USD; *P*<.001) (Table 2).

²⁰⁵ Compared with the low- and high-dose groups, the standard-dose group showed lower

- 208 No patients had Reye syndrome. There were no significant differences between the
- 209 groups in the proportion of other adverse events (bleeding from the upper gastrointestinal
- tract, anemia, gastric ulcer, and liver function abnormality) (Table 1).
- 211 In the sensitivity analysis, CAAs were confirmed in 527 patients (0.6%) among the study
- 212 participants. Similar to the main analysis, the standard dose group showed the lowest
- **213** proportion of CAAs (0.6%, *P*<.001).
- 214 Regarding restricted cubic spline functions, tests for overall association and non-linear
- 215 association showed significant non-linear relationships between aspirin dose and the
- 216 outcomes. In comparison with an aspirin dose of 30 mg/kg/day, the odds ratio (95%
- 217 confidence interval [CI]) for CAA was 1.40 (1.13–1.75) at 5 mg/kg/day. For aspirin doses
- of 30 mg/kg/day or higher, the 95% CIs for the occurrence of CAA were almost across 1
- and not significantly different when compared with the values observed at 30 mg/kg/day

- 221 The odds ratio (95% CI) for IVIG resistance was 0.87 (0.76–1.0) at the aspirin dose of 5
- 222 mg/kg/day and 0.59 (0.36–0.98) at 80 mg/kg/day when compared with 30 mg/kg/day
- 223 (Figure 3). The difference (95% CI) in the length of stay was 0.33 (0.15–0.5) days at 5
- mg/kg/day and 2.32 (1.61–3.03) days at 80 mg/kg/day with reference to 30 mg/kg/day

²²⁰ (Figure 2).

225	(Figure 4).	The difference in	medical costs was	55.8 (42.8-1)	54.4) USD at	5 mg/kg/day
-----	-------------	-------------------	-------------------	---------------	--------------	-------------

- and -2,307 (-2,707-1, 907) USD at 80 mg/kg/day when compared with the values
- observed at 30 mg/kg/day (Figure 5).
- 228 In the sensitivity analysis for CAA, the odds ratio (95% CI) for CAA was 1.86 (1.33–
- 229 2.59) at 5 mg/kg/day compared with the values observed at 30 mg/kg/day. For aspirin
- doses of 30 mg/kg/day or higher, the 95% CIs for CAA were across 1 and not
- significantly different when compared with the values observed at 30 mg/kg/day (Figure
- **232** 6).
- 233
- 234
- 235
- 236

237

238 Discussion

239	Our study evaluated serial aspirin doses from low (3 mg/kg/day) to high doses (90
240	mg/kg/day). Aspirin was generally considered to have antiplatelet effects at low doses
241	and anti-inflammatory effects at standard or high doses. In this study, we examined a
242	larger number of patients than those in previous studies and found that low-dose aspirin
243	was significantly associated with a higher proportion of CAA. We also found that
244	standard and high doses (over 50 mg/kg/day) of aspirin did not significantly change the
245	occurrence of CAA.
246	The results of previous studies were inconsistent regarding the association between
247	aspirin dose and CAA occurrence. ^{6,10,11,16} Our results suggest that at least an
248	anti-inflammatory dose of aspirin may be needed to reduce inflammation and prevent
249	CAA in KD, and aspirin above the anti-inflammatory dose may neither suppress nor
250	enhance the inflammatory response of patients with acute KD. Since these mechanisms
251	are unknown, further basic research on KD is required to elucidate these mechanisms.
252	We showed that the low-dose and high-dose aspirin (>50 mg/kg/day) was associated with
253	less proportion of IVIG resistance in patients with acute KD. Some previous reports
254	indicated that lower aspirin doses may increase IVIG resistance, ^{7,8,16} while others showed

255	no significant difference in aspirin dose for IVIG resistance. ^{4-6,9} The reason is unknown;
256	however, clinicians may use low-dose aspirin in mild cases of patients with acute KD.
257	The present study showed that the use of high-dose aspirin (over 50 mg/kg/day) was
258	associated with a shorter length of hospital stay and lower medical costs. Previous studies
259	reported similar results for length of stay due to faster resolution of fever. ^{17,18} Considering
260	the results for length of stay and medical costs, the use of high-dose aspirin (over 50
261	mg/kg/day) may have resulted in early discharge from the hospital due to early resolution
262	of fever, thus resulting in lower medical costs.
263	The present study examined possible adverse effects of aspirin and found no association
263 264	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG
263 264 265	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed
263 264 265 266	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day. ¹⁹ Many
263 264 265 266 267	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day. ¹⁹ Many previous studies reported liver dysfunction due to KD inflammation, while liver
263 264 265 266 267 268	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day. ¹⁹ Many previous studies reported liver dysfunction due to KD inflammation, while liver dysfunction due to Reye's syndrome was shown in patients with aspirin doses of 100
263 264 265 266 267 268 269	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day. ¹⁹ Many previous studies reported liver dysfunction due to KD inflammation, while liver dysfunction due to Reye's syndrome was shown in patients with aspirin doses of 100 mg/kg/day. ^{20,21} In our study, no cases of Reye syndrome were encountered. In general,
263 264 265 266 267 268 269 270	The present study examined possible adverse effects of aspirin and found no association between aspirin dose and adverse effects. A previous study showed anemia after IVIG treatment in patients who received over 30 mg/kg/day of aspirin. ⁵ Another study showed gastrointestinal hemorrhage related to high-dose aspirin over 70 mg/kg/day. ¹⁹ Many previous studies reported liver dysfunction due to KD inflammation, while liver dysfunction due to Reye's syndrome was shown in patients with aspirin doses of 100 mg/kg/day. ^{20,21} In our study, no cases of Reye syndrome were encountered. In general, side effects are often dose-dependent; but in this study, the proportion of side effects in

272 <u>Limitations</u>

273	We acknowledge several limitations in this study. First, our database lacked data
274	regarding KD symptoms, laboratory findings, and fever duration of patients with acute
275	KD. It is impossible to know from our database the days of illness during admission of the
276	patient to the hospital. Therefore, we considered the days of hospital stay as days of
277	illness. Patients who received steroids or cyclosporine are likely to have a higher severity
278	of KD as per the Japanese Kawasaki disease score for severity classification. ^{22,23} Second,
279	the severity of CAAs due to KD, which was expressed as coronary arterial diameters or Z
280	scores, was not included in our database. To clarify that CAAs were not transient, we used
281	the history of cardiac catheterization and the prescription history of anticoagulants in
282	addition to aspirin for sensitivity analysis. Third, adverse events due to aspirin were
283	identified with recorded diagnoses, but these may have been underreported. Fourth, a few
284	patients in our database used aspirin at doses greater than 90 mg/kg/day. Finally, because
285	most of the patients in this study were Japanese and the generalizability of the present
286	results to other populations may be limited.

287 Conclusion

- 288 The results showed no significant association between aspirin escalation and CAAs in
- 289 patients with acute KD. High-dose aspirin showed the potential to reduce hospital stay
- and medical costs without increasing complications.

291 Acknowledgements

292	Funding Source: This work was supported by grants from the Ministry of Health,
293	Labour and Welfare, Japan (21AA2007 and 22AA2003) and the Ministry of Education,
294	Culture, Sports, Science and Technology, Japan (20H03907).
295	Financial Disclosure: None of the authors have any financial relationships relevant to
296	this article to disclose.
297	Conflict of Interest: None of the authors have any potential conflict of interest to
298	disclose.
299	
300	
301	
302	
303	
304	
305	
306	
307	
308	
309	
311	
312	
313	
314	
315	

316 References

- 317 1. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol.
- **318** 2016;67(14):1738-1749.
- 319 2. Mccrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term
- 320 management of Kawasaki disease: A scientific statement for health professionals from
- 321 the American Heart Association. *Circulation*. 2017;135(17):e927-e999.
- 322 3. Miura M, Ayusawa M, Ito S. The guidelines on acute stage Kawasaki disease treatment.
- 323 Pediatr Cardiol Card Surg. 2020;36(suppl 1):S1.1-S1.29.
- 4. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute
- 325 Kawasaki disease: aspirin's role in the febrile stage revisited. *Pediatrics*.
- **326** 2004;114(6):e689-e693.
- 327 5. Kuo HC, Lo MH, Hsieh KS, Guo MMH, Huang YH. High-dose aspirin is associated
- 328 with anemia and does not confer benefit to disease outcomes in Kawasaki disease. *PLOS*
- 329 *ONE*, Woo PC, ed. 2015;10(12):e0144603.
- 330 6. Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary
- abnormalities in Kawasaki disease. *Pediatrics*. 2017;139(6):e20170098.
- 7. Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute
 Kawasaki disease and patient outcomes. *J Pediatr.* 2017;184:125-129.e1.
- 8. Zheng X, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial
 treatment of Kawasaki disease: current evidence based on a meta-analysis, editor. *PLOS ONE*. 2019;14(5):e0217274.
- 337 9. Jia X, Du X, Bie S, Li X, Bao Y, Jiang M. What dose of aspirin should be used in the
- initial treatment of Kawasaki disease? A meta-analysis. *Rheumatology (Oxford)*.
 2020;59(8):1826-1833.
- 340 10. Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in
 341 inpatient hospital settings in the United States. *Pediatrics*. 2010;126(4):647-655.
- 342 11. Yumoto T, Naito H, Yorifuji T, Aokage T, Fujisaki N, Nakao A. Association of Japan
- 343 Coma Scale score on hospital arrival with in-hospital mortality among trauma patients.
- 344 *BMC Emerg Med.* 2019;19(1):65.

- 345 12. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in
- 346 multiple regression: a bad idea. *Stat Med.* 2006;25(1):127-141.
- 347 13. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline
- 348 functions in public health research. *Stat Med.* 2010;29(9):1037-1057.
- 349 14. Ito Y, Matsui T, Abe K, et al. Aspirin dose and treatment outcomes in Kawasaki
- disease: A historical control study in Japan. Front Pediatr. 2020;8:249.
- 351 15. Nakada T. Effects of anti-inflammatory drugs on intravenous immunoglobulin
- therapy in the acute phase of Kawasaki disease. *Pediatr Cardiol*. 2015;36(2):335-339.
- 353 16. Lau AC, Duong TT, Ito S, Yeung RSM. Intravenous immunoglobulin and salicylate
- differentially modulate pathogenic processes leading to vascular damage in a model of
- 355 Kawasaki disease. Arthritis Rheum. 2009;60(7):2131-2141.
- 356 17. Akagi T, Kato H, Inoue O, Sato N. A study on the optimal dose of aspirin therapy in
- 357 Kawasaki disease—clinical evaluation and arachidonic acid metabolism. *Kurume Med J*.
 358 1990;37(3):203-208.
- 18. Lee G, Lee SE, Hong YM, Sohn S. Is high-dose aspirin necessary in the acute phase
 of Kawasaki disease? *Korean Circ J.* 2013;43(3):182-186.
- 361 19. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal
- 362 hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr.
- **363** 1996;128(5 Pt 1):701-703.
- 364 20. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye's syndrome
- 365 developing in an infant on treatment of Kawasaki syndrome. *J Paediatr Child Health*.
- **366** 2005;41(5-6):303-304.
- 21. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one
 case. *Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi*. 1992;33(1):67-71.
- 369 22. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for
- 370 prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a
- arandomised, open-label, blinded-endpoints trial. *Lancet*. 2012;379(9826):1613-1620.
- 372 23. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with
- 373 immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in

- 374 patients with Kawasaki disease predicted to be at increased risk of non-response to
- 375 intravenous immunoglobulin (KAICA): a randomised controlled, open-label,
- 376 blinded-endpoints, phase 3 trial. *Lancet*. 2019;393(10176):1128-1137.

Table 1. Patients Characteristics

	Total	Low-dose group	Standard-dose group	High-dose group	D 1
Variables	(N = 82109)	(N=30349)	(N=49646)	(N=2024)	P value
Age (years), mean (SD)	2.1 (2.0)	2.2 (2.1)	2.1 (2.0)	2.1 (2.1)	<.001
Male (%)	47277 (57.6%)	17553 (57.7%)	28561 (57.5%)	1163 (57.5%)	.92
Weight (kg), mean (SD)	12.3 (4.7)	12.5 (5.0)	12.1 (4.4)	11.2 (4.8)	<.001
Height (cm), mean (SD)	77.5 (32.0)	78.4 (30.8)	76.9 (32.8)	76.4 (29.2)	<.001
Hospital days of illness at initial IVIG,					
median (IQR)	2 (1.0-2.0)	2 (1.0-2.0)	2 (1.0-2.0)	2 (1.0-3.0)	.002
Total amount of initial aspirin (mg/kg/day),					
median (IQR)	30.1 (29.4-32.3)	28.9 (27.5-29.5)	31.1 (30.2-36.4)	52.1 (50.8-58.5)	<.001
Use of 10% IVIG	9266 (11.5%)	3351 (11.2%)	5626 (11.5%)	289 (14.5%)	<.001
Initial steroid use	8451 (10.3%)	3445 (11.3%)	4830 (9.7%)	176 (8.7%)	<.001
Initial cyclosporine use	233 (0.3%)	99 (0.3%)	120 (0.2%)	14 (0.7%)	<.001
Adverse event after admission					
Reye syndrome	0	0	0	0	
Bleeding from the upper gastrointestinal					
tract	340 (0.4%)	135 (0.4%)	200 (0.4%)	5 (0.2%)	.34
Anemia	735 (0.9%)	278 (0.9%)	432 (0.9%)	25 (1.2%)	.21
Gastric ulcer	762 (0.9%)	281 (0.9%)	463 (0.9%)	18 (0.9%)	.97
Liver function abnormality	216 (0.3%)	78 (0.3%)	135 (0.3%)	3 (0.1%)	.54
Type of hospital					<.001
Academic hospital	15092 (20.6%)	6111 (22.2%)	8405 (19.1%)	576 (32.3%)	
Complex Chronic Conditions					
0-1	78846 (96.0%)	29201 (95.9%)	47722 (96.1%)	1923 (95.0%)	.024
$2 \leq$	3263 (4.0%)	1238 (4.1%)	1924 (3.9%)	101 (5.0%)	
Transportation by ambulance	1928 (2.3%)	758 (2.5%)	1100 (2.2%)	70 (3.5%)	<.001
Japan coma scale at admission					.464
Alert	81454 (99.2%)	30181 (99.2%)	49265 (99.2%)	2008 (99.2%)	
Not Alert	655 (0.8%)	258 (0.8%)	381 (0.8%)	16 (0.8%)	
Transported from another hospital	63212 (77.0%)	23869 (78.4%)	37865 (76.3%)	1478 (73.0%)	<.001
Hospital volume					
Low (1-29.0)	25255 (30.8%)	8876 (29.2%)	15871 (32.0%)	508 (25.1%)	<.001
Middle (29.0-53.5)	28233 (34.4%)	10678 (35.1%)	16971 (34.2%)	584 (28.9%)	
High (≥ 53.6)	28621 (34.9%)	10885 (35.8%)	16804 (33.8%)	932 (46.0%)	

IQR: interquartile range; IVIG: intravenous immunoglobulin; SD: standard deviation

Variables	Total	Low-dose group	Standard-dose group	High-dose group	Davahua
	(N =82109)	(N =30439)	(N=49646)	(N=2024)	P value
Proportion of CAAs (%)	1817 (2.2%)	741 (2.4%)	1014 (2.0%)	62 (3.1%)	<.001
Proportion of IVIG resistance (%)	15717 (19.1%)	5403 (17.8%)	9765 (19.7%)	549 (27.1%)	<.001
Length of stay (day)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	10.0 (8.0-13.0)	<.001
Medical cost (USD)	6454 (5299-8169)	6461 (5299-8184)	6440 (5292-8139)	6806 (5470-8895)	<.001
Proportion of CAAs (sensitivity analysis **) (%)	527 (0.6%)	227 (0.7%)	281 (0.6%)	19 (0.9%)	.002

Table 2. Comparison of outcomes among the three groups with different doses of Aspirin

CAAs: coronary artery abnormalities; IVIG: intravenous immunoglobulin; USD: United States dollars

* All data are presented as medians (interquartile ranges).

** CAA in the sensitivity analysis was defined as a diagnosis of CAA (the main analysis was diagnosis only) and drug therapy (warfarin or clopidogrel) and/or cardiac catheterization.

Figure legends

Figure 1. Flow chart for the study cohort

ICD-10: International Classification of Diseases, Tenth Revision; IVIG: intravenous immunoglobulin; KD: Kawasaki disease

Figure 2. Restricted cubic spline for coronary artery abnormalities

The dose-response relationship between aspirin dose and proportion of coronary artery abnormalities was adjusted by analysis using a

restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95%

CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 3. Restricted cubic spline for intravenous immunoglobulin resistance

The dose–response relationship between aspirin dose and proportion of intravenous immunoglobulin resistance was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 4. Restricted cubic spline for length of hospital stay

The dose-response relationship between aspirin dose and the length of hospital stay was adjusted by analysis using a restricted cubic

spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 5. Restricted cubic spline for total medical cost

The dose–response relationship between aspirin dose and the total medical cost was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50, and 70 mg/kg/day) The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval

Figure 6. Restricted cubic spline for coronary artery abnormalities in the sensitivity analysis

The dose–response relationship between aspirin dose and proportion of coronary artery abnormalities in the sensitivity analysis (limited to those with anticoagulant use or cardiac catheterization as well as diagnosis of coronary artery abnormalities) was adjusted by analysis using a restricted cubic spline with five knots (Aspirin, 10, 30, 40, 50 and 70 mg/kg/day). The graphs show the estimated values along with 95% CI.

IVIG: intravenous immunoglobulin; CI: confidence interval











